Rezultati pretraživanja
  1. Spring Bank Pharmaceuticals Inc to Post FY2019 Earnings of -$1.67 Per Share, Jefferies Financial Group Forecasts

  2. prije 8 sati

    Jefferies Financial Group Raises Spring Bank Pharmaceuticals FY2019 Earnings Estimates to ($1.67) EPS (Previously ($1.69)).

  3. 31. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    and at least have a decent shot

  4. 30. sij

    trading at half of cash...buy, sell or hold?

  5. 30. sij

    NEW ARTICLE : Canaccord likes Madrigal Pharma in premarket analyst action

  6. 30. sij
    Odgovor korisnicima

    I’m leery of an HBV-ASO treatment dosed more frequently/maybe at higher concentrations than RNAi-based HBV Drug. IRIG dosed orally 400mg-D might have been to strong for patients w hepatic decompensation. I’m no expert, just my thoughts.

  7. 29. sij

    Who's not: : -21.76%, : -20.07%, : -19.94%

  8. 29. sij

    Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV

  9. 29. sij
  10. 29. sij

    Non scientist question. Does the failure of inarigivir have read through to any other players in the HBV combo arena that may be using something with a similar MOA? So far, the RNAi components look safe.

  11. 29. sij

    Anyone buying ?

  12. 29. sij
  13. 29. sij

    PM Down Gappers (Low Float):

  14. 29. sij

    Spring Bank Pharma decision comes after patient died in phase 2 trial

  15. 29. sij

    Will resume 09:00:00. News and Resumption Times. (Halted: 08:25:01)

  16. TRADING HALT: via →

  17. 29. sij

    halt alert (T1). Last Price 1.70 (Last Vol = 107.06K). Halt alerts in real-time via SMS and Push Notifications at

  18. 28. sij

    come on springbank pharma get that funding for your vaccine now don't miss out

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.